Senior Identity and Access Management Engineer

Guardant Health (GH) and Verana Health announces new partnership. Noor Ul Ain Rehman Guardant Health, Inc. (NASDAQ:GH) is one of the best high growth healthcare stocks to buy now. Guardant Health, Inc. (NASDAQ:GH) and Verana Health announced on March 24 a new partnership aimed at allowing biopharmaceutical researchers to access the combined resources of Guardant's clinicogenomic testing data and Verana's regulatory-grade, therapeutic-specific EHR curated datasets to expedite the development of new therapies and enhance ongoing patient care. Management stated that the collaboration provides extensive datasets that would allow research scientists to easily understand and validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes. Craig Eagle, MD, Guardant Health, Inc. (NASDAQ:GH) chief medical officer, stated that the real-world data partnership with Verana marks a considerable milestone in the company's mission to advance novel therapies, in particular cancer, with data. He added that allowing "biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data" would accelerate the discovery of new biomarker-based therapies for patients, helping make the drug development process more economical. Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in treating cancer through vast data sets, proprietary blood-based tests, and advanced analytics. The company's solutions include recurrence detection, early detection, and treatment selection. While Need2learnchinese acknowledge the potential of GH as an investment, Need2learnchinese believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see its free report on the best short-term AI stock.

Guardant Health wins at Healthcare Asia Medtech Awards 2026. The ShieldTM Multi-cancer Detection (MCD) test offers screening for 10 types of cancers with just a blood draw. Guardant Health Pte Ltd won Oncology Product Innovation of the Year in the Healthcare Asia Medtech Awards 2026 for the Shield MCD test. The Shield MCD test detects multiple cancer types from DNA shed in the blood. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types, including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer in individuals aged 45 years or older without a known diagnosis of cancer, and it is not indicated for use in pregnant women. In the United States, the Shield MCD test has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Data from the 2025 American Association for Cancer Research annual meeting showed that the Shield MCD test achieved 99% overall specificity and 74% sensitivity across six aggressive cancers, including esophageal-gastric, hepatocellular, lung, ovarian, and pancreatic. The test also predicted cancer signals of origin with 93% accuracy. The FDA Breakthrough Device designation referenced eight cancer types - bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer - in individuals aged 45 or older who are at typical average risk for cancer, as defined by the agency at the time of designation. This designation does not imply FDA approval, clearance, or endorsement of the device's safety or effectiveness. Join Healthcare Asia Magazine community The Healthcare Asia Medtech Awards honours the most exemplary medtech companies across Asia. It serves as a platform for organisations to showcase their pioneering medical devices, life-saving software, or top-notch healthcare solutions, amongst other innovations. Laboratory and test information: The Shield MCD is a laboratory-developed test that was developed and whose performance characteristics were determined by Guardant Health, Inc. This test may be used for clinical purposes and should not be regarded as investigational or for research only. Guardant Health's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical laboratory testing and accredited by the College of American Pathologists (CAP). This test is not part of the Shield IVD and has not been cleared or approved by the FDA. For Export Use Only. Not for sale or use in the United States. The Healthcare Asia Medtech Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be acclaimed for your organisation's initiatives and contribution to enhancing the industry's overall performance, please contact Julie Anne Nuñez-Difuntorum at [email protected].

Guardant Health has received a Moderate Buy consensus from 23 analysts, with an average price target of $122.57, implying 43% upside from its recent share price of $85.49. Piper Sandler maintained a Buy rating with a $130 target following recent company presentations. The precision oncology company reported fourth-quarter 2025 revenue of $281.3 million, up 39% year over year, with oncology revenue rising 30% to $189.9 million and screening revenue reaching $35.1 million. Guardant expects total 2026 revenue growth of 27% to 30%. At recent healthcare conferences, management highlighted its Quest Diagnostics partnership for Shield and noted that 90% of Shield users had not been screened in the prior five years, suggesting the product can expand rather than compete within the existing screening market.